Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 0.90 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.43 |
| ▸ | CTRL | P40313 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886406 | 0.96 | OPRK1 (0.86) | OPRK1OPRM1MMP1MMP3 | |
| SCHEMBL21886569 | 0.95 | OPRK1 (0.90) | OPRK1OPRM1 | |
| SCHEMBL10316418 | 0.95 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL21286531 | 0.92 | OPRK1 (0.76) | OPRK1OPRM1MMP1MMP3 | |
| SCHEMBL24001251 | 0.91 | OPRK1 (0.78) | OPRK1OPRM1MMP1MMP3 | |
| SCHEMBL12243573 | 0.90 | OPRK1 (0.96) | OPRK1OPRM1 | |
| SCHEMBL13290878 | 0.90 | OPRK1 (0.91) | OPRK1OPRM1 | |
| SCHEMBL10316456 | 0.90 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL21886398 | 0.89 | OPRK1 (0.72) | OPRK1TMPRSS11DCTRLMMP1MMP3 | |
| SCHEMBL19249320 | 0.89 | OPRK1 (0.99) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-10793596-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885OPRM1 4/4885TMPRSS11D 791/4885 |
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885TMPRSS11D 2519/4885 |
| US-10793596-B2 | Synthetic peptide amides | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885OPRM1 4/4885TMPRSS11D 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.